Andere Sprachen Citius Pharmaceuticals, Inc.

Aktien

A2DXS0

US17322U2078

CTXR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
0,5837 ^USD	-8,54 %		-4,15 %	-22,84 %

21.05.	Citius Pharmaceuticals, Inc. Erreicht primäre und sekundäre Endpunkte in Phase 3-Studie mit Mino-Lok Antibiotic Lock Solution	CI
14.05.	Citius Pharmaceuticals, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	29.05.
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	21.05.
Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	21.05.
Citius Pharmaceuticals : CTXR Factsheet	15.05.
Citius Pharmaceuticals : CTXR Corporate Presentation	15.05.
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update	14.05.
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	14.05.
Citius Pharmaceuticals to Participate In Upcoming EF Hutton and H.C. Wainwright Investor Conferences	13.05.
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences	10.05.
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering	30.04.
Citius Pharmaceuticals Launches $15 Million Offering	26.04.
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering	26.04.
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11.04.
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11.04.
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference	04.04.
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	18.03.
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	18.03.
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program	07.03.
Citius Pharmaceuticals to Participate In Upcoming BIO CEO and Sidoti Investor Conferences	26.02.
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Citius Pharmaceuticals, Inc.

Aktien

A2DXS0

US17322U2078

CTXR

Andere Sprachen

Filter